Boule Diagnostics AB OMXSTO:BOUL:
ANNOUNCES CFO DEPARTURE FOR NEW OPPORTUNITY
HOLGER LEMBRÉR, CHIEF FINANCIAL OFFICER, WILL BE LEAVING COMPANY
Boule Diagnostics CFO Leaves Company
Watch Boule Diagnostics' latest callBoule Diagnostics (Stockholm:BOUL) Q3 2026 Earnings Call · Replay · Oct 23Read the transcript of Boule Diagnostics (Stockholm:BOUL) Q3 2026 Earnings CallEarlier from Boule Diagnostics
- BOUL: Instrument sales surged 17% but lower prices and costs led to margin decline; cash flow turned positive
- BOUL: Sales fell 25% YoY, but margins improved and OEM growth offset hematology weakness
- BOUL: Margins improved and cost savings realized, with OEM growth and new U.S. distribution boosting outlook
- BOUL: Sales declined, but margins and EBIT improved amid restructuring and strong OEM growth
- BOUL: Sales declined but margins improved; restructuring aims to boost profitability
Later from Boule Diagnostics
- BOUL: Organic growth and strong instrument sales drive improved cash flow amid margin pressure
- Boule Diagnostics CEO Torben Nielsen To Leave Company
- Boule Diagnostics Selected As Provider In Tender In Italy
- Boule Diagnostics Appoints Michael Af Winklerfelt As CFO
- Boule Diagnostics Renews, Expands Global Supply Agreement
Follow Boule Diagnostics into a list and get an email when it puts out news.
Follow Boule Diagnostics